Sotorasib: a KRAS inhibitor for non-small cell lung cancer.
作者信息
Ganguly Arghya, Yoo Euna
机构信息
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
出版信息
Trends Pharmacol Sci. 2022 Jun;43(6):536-537. doi: 10.1016/j.tips.2022.03.011. Epub 2022 Apr 21.
Abstract
摘要
相似文献
1
Sotorasib: a KRAS inhibitor for non-small cell lung cancer.
Trends Pharmacol Sci. 2022 Jun;43(6):536-537. doi: 10.1016/j.tips.2022.03.011. Epub 2022 Apr 21.
2
KRAS Inhibitor Resistance in -Amplified Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7.
3
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573.
4
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Future Oncol. 2024 Jan;20(3):113-120. doi: 10.2217/fon-2023-0560. Epub 2023 Nov 27.
5
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Eur J Cancer. 2024 Apr;201:113911. doi: 10.1016/j.ejca.2024.113911. Epub 2024 Feb 14.
6
BCL-X PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS-mutated cancers.
J Hematol Oncol. 2022 Mar 9;15(1):23. doi: 10.1186/s13045-022-01241-3.
7
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
Future Oncol. 2025 Jan;21(1):63-71. doi: 10.1080/14796694.2024.2430172. Epub 2024 Nov 27.
8
Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024 Sep;19(9):e43. doi: 10.1016/j.jtho.2024.06.015.
9
A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024 Sep;19(9):e44-e45. doi: 10.1016/j.jtho.2024.07.001.
10
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
Cell Commun Signal. 2024 Jun 12;22(1):324. doi: 10.1186/s12964-024-01667-x.
引用本文的文献
1
Advancing Covalent Ligand and Drug Discovery beyond Cysteine.
Chem Rev. 2025 Jul 23;125(14):6653-6684. doi: 10.1021/acs.chemrev.5c00001. Epub 2025 May 22.
2
RNA splicing alterations in lung cancer pathogenesis and therapy.
Cancer Pathog Ther. 2023 Apr 28;1(4):272-283. doi: 10.1016/j.cpt.2023.04.004. eCollection 2023 Oct.
3
HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis.
Sci Adv. 2023 Jun 9;9(23):eade1155. doi: 10.1126/sciadv.ade1155.
4
Sotorasib: First Approved Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer.
Curr Med Chem. 2023;30(9):1000-1002. doi: 10.2174/0929867329666220907161505.
5
The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine.
Pharmaceuticals (Basel). 2022 Aug 14;15(8):999. doi: 10.3390/ph15080999.
本文引用的文献
1
Sotorasib: First Approval.
Drugs. 2021 Sep;81(13):1573-1579. doi: 10.1007/s40265-021-01574-2.
2
Sotorasib for Lung Cancers with p.G12C Mutation.
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
3
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
4
Discovery of a Covalent Inhibitor of KRAS (AMG 510) for the Treatment of Solid Tumors.
J Med Chem. 2020 Jan 9;63(1):52-65. doi: 10.1021/acs.jmedchem.9b01180. Epub 2019 Dec 24.
5
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
6
AMG 510 First to Inhibit "Undruggable" KRAS.
Cancer Discov. 2019 Aug;9(8):988-989. doi: 10.1158/2159-8290.CD-NB2019-073. Epub 2019 Jun 12.
7
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.
8
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.
Zotero 插件